SAHPRA to commence review of COVID-19 vaccine registration applications

SAHPRA will prioritise all COVD-19 applications and will apply an expedited approach to health products, including vaccines.

With the advent of COVID-19, vaccine development is a critical area of need. SAHPRA has been proactive and is prepared for the vaccine registration process. The readiness programme includes the establishment of a specialised working group, the COVID-19 Vaccine Registration Working Group (CVr WG) comprising both external and internal SAHPRA experts specialising in areas of vaccinology, manufacturing, clinical trials, epidemiology, vigilance and other specialisations informing quality, safety and efficacy of the products and this case vaccines.

Vaccination Image by Angelo Esslinger from Pixabay
The development and authorisation of COVID-19 vaccines must be supported by toxicology and safety studies in relevant animal models in compliance with the international standards of Good Laboratory Practices

Vaccine registration

For vaccines registration, the expedited process will include using approaches such as:

• Performing rolling reviews of submissions, that is reviewing data that is available and accepting ongoing data in batches for review.

• Reliance on regulatory work done by other regulators that SAHPRA aligns with

• A collaborative approach through the World Health Organisation (WHO)

SAHPRA may issue terms and conditions requiring the applicant to provide additional data confirming the elements of safety, quality and efficacy.

“SAHPRA will review the safety and efficacy of each vaccine on a case-by-case basis and will only grant approval for public use once it has met acceptable standards of quality, safety and efficacy,” indicates Dr Boitumelo Semete-Makokotlela, CEO of SAHPRA.

Once this approval takes place the National Department of Health (NDoH) will determine access, roll out strategy and distribution.

Safety studies

Vaccines can prevent disease and also have adverse effects in some individuals. SAHPRA has a mandate to monitor such adverse effects and ensure that they are recorded and managed properly so that, regulatory action can be taken. The development and authorisation of COVID-19 vaccines must be supported by toxicology and safety studies in relevant animal models in compliance with the international standards of Good Laboratory Practices (GLP). If the candidate COVID- 19 vaccine is to be used in pregnant women, then developmental and reproductive toxicity studies must be conducted to better understand the risks.

SAHPRA achieves this through its Pharmacovigilance Unit. Reports of suspected adverse events following immunization can be submitted on the SAHPRA website.

The public is encouraged to report their suspected vaccine-related complaints through their healthcare provider at the healthcare facility from which the vaccination was administered to ensure that all important and relevant facts are captured on the reporting form to enable proper investigation and handling of the vaccine-related complaint.



Latest


22 Jan 2021
Clere celebrates 60 years of spreading the love for skin

This year heritage skin care brand, Clere is celebrating its 60th anniversary. “The name Clere has been synonymous with soft,…

Clere celebrates 60 years of spreading the love for skin

This year heritage skin care brand, Clere is celebrating its 60th anniversary. “The name Clere has been synonymous with soft, smooth, beautiful looking skin for six decades now. It’s a favourite in both South African homes and those abroad. Over the years Clere has managed to remain relevant, and up…

21 Jan 2021
COVID-19 vaccine – how will Africa keep it cold enough?

While we await the first vaccines to either arrive in the country via air, or under licence from local manufactured…

COVID-19 vaccine – how will Africa keep it cold enough?

While we await the first vaccines to either arrive in the country via air, or under licence from local manufactured sources, there remains another obstacle. The so-called cold supply chain that needs to remain intact when delivering the COVID-19 vaccine to all corners of the country. The temperatures needed for…

18 Jan 2021
Solvay commits to sustainable cyclopentanone production

Solvay has begun a process of decarbonising the cyclopentanone unit of its Melle plant in France. Through an agreement with…

Solvay commits to sustainable cyclopentanone production

Solvay has begun a process of decarbonising the cyclopentanone unit of its Melle plant in France. Through an agreement with an agricultural cooperative for the next 15 years, the entire cyclopentanone production will indeed rely solely on biomethane gas, a green source of energy. The cooperative built a facility to…

18 Jan 2021
Irene Cantos becomes IMCD’s group director Personal Care

IMCD has appointed Irene Cantos as business group director Personal Care, effective 6 January 2021. In her role, Cantos, will…

Irene Cantos becomes IMCD’s group director Personal Care

IMCD has appointed Irene Cantos as business group director Personal Care, effective 6 January 2021. In her role, Cantos, will lead the Business Group Personal Care in becoming the global player of choice for both suppliers and customers in the distribution of speciality ingredients. The group aims to grow both…


Top stories


25 Jun 2020
How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a…

How to ensure business agility in a pandemic

BY: Neil Birch, CEO at Novus Holdings Business agility is the capability of a business to respond quickly to a changing environment, whether it be internal or external. Qualities of agile businesses include being adaptive, flexible and creative in your response to change without losing momentum (remaining productive) or vision.…

01 May 2020
Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex,…

Fibertex manufactures critical components for COVID-19 PPE

Fibertex SA, part of the global Fibertex Nonwovens group, has developed versatile high-performance components for protective facemasks and respirators. “Fibertex, which continuously invests in technological advancements to meet requirements in diverse industries – has increased production capacity of materials so desperately needed during the global COVID-19 pandemic,” explains Rosa Naidoo,…

23 Apr 2020
Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love.…

Are you South Africa’s best female entrepreneur?

Entries are now open for the Santam Women of the Future Awards 2020 in association with Fairlady and True Love. Santam, Fairlady and, for the first time this year, Truelove Magazine, have partnered up in the search to find the best female entrepreneurs in the country. Best women entrepreneurs If…

30 Nov 2017
Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form…

Rooibos could reduce risk of “Type 3” diabetes – a precursor to Alzheimer’s

Researchers at Warren Alpert Medical School at Brown University in the US found a link between a relatively new form of diabetes, known as “type 3” diabetes and Alzheimer’s disease.


Visit the official COVID-19 government website to stay informed: sacoronavirus.co.za